Macquarie Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Macquarie Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,684	Closed	-$4.72K	–	2475
2022 Q2	$5K	Hold	1,684	–	–	﹤0.01%	2515
2022 Q1	$7K	Hold	1,684	–	–	﹤0.01%	2546
2021 Q4	$8K	Hold	1,684	–	–	﹤0.01%	2533
2021 Q3	$9K	Hold	1,684	–	–	﹤0.01%	2546
2021 Q2	$9K	Hold	1,684	–	–	﹤0.01%	2477
2021 Q1	$11K	Sell	1,684 -798	-32%	-$4.42K	﹤0.01%	2374
2020 Q4	$11K	Hold	2,482	–	–	﹤0.01%	2294
2020 Q3	$10K	Hold	2,482	–	–	﹤0.01%	2279
2020 Q2	$12K	Buy	+2,482	New	+$10.2K	﹤0.01%	2260
2018 Q3	–	Sell	-30,900	Closed	-$507K	–	2147
2018 Q2	$507K	Buy	+30,900	New	+$542K	﹤0.01%	1363

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's AMRX Position: Q3 2022 in Review

Macquarie Group sold out of Amneal Pharmaceuticals (AMRX) in Q3 2022, closing a stake of 1,684 shares — an estimated $4.72K sold.

Macquarie Group first reported a position in AMRX in Q2 2018 and held it in 10 quarters. The position peaked at $507K in Q2 2018. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2022.

Macquarie Group reported no remaining Amneal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Macquarie Group sold 1,684 Amneal Pharmaceuticals shares in Q3 2022, an estimated $4.72K.
Macquarie Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Macquarie Group's Amneal Pharmaceuticals position peaked at $507K in Q2 2018.
154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.